Notch signaling and efficacy of PD-1/PD-L1 blockade in relapsed small cell lung cancer
Immune checkpoint blockade (ICB) benefits only a small subset of patients with small cell lung cancer (SCLC) and the mechanisms driving benefit are poorly understood. Here, the authors show that elevated Notch signaling predicts clinical benefit in ICB in relapsed SCLC.
Guardado en:
Autores principales: | Nitin Roper, Moises J. Velez, Alberto Chiappori, Yoo Sun Kim, Jun S. Wei, Sivasish Sindiri, Nobuyuki Takahashi, Deborah Mulford, Suresh Kumar, Kris Ylaya, Christopher Trindade, Irena Manukyan, Anna-Leigh Brown, Jane B. Trepel, Jung-Min Lee, Stephen Hewitt, Javed Khan, Anish Thomas |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Nature Portfolio
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/14cd7395b4e240a6a4c5e9753ff63101 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Molecular mechanism of PD-1/PD-L1 blockade via anti-PD-L1 antibodies atezolizumab and durvalumab
por: Hyun Tae Lee, et al.
Publicado: (2017) -
Potential Biomarkers for the Efficacy of PD-1-PD-L Blockade in Cancer
por: Grecea M, et al.
Publicado: (2021) -
Depletion of PD-1 or PD-L1 did not affect the mortality of mice infected with Mycobacterium avium
por: Masayuki Nakajima, et al.
Publicado: (2021) -
Targeting PD-1/PD-L1 in lung cancer: current perspectives
por: González-Cao M, et al.
Publicado: (2015) -
Selective inhibition of TGF-β1 produced by GARP-expressing Tregs overcomes resistance to PD-1/PD-L1 blockade in cancer
por: Grégoire de Streel, et al.
Publicado: (2020)